Methods of treating mild cognitive impairment (MCI) and related disorders

Patent metadata

Field	Value
Publication number	US-10449177-B2
Application number	US-201113213960-A
Country	US
Kind code	B2
Filing date	Aug 19, 2011
Priority date	Aug 19, 2010
Publication date	Oct 22, 2019
Grant date	Oct 22, 2019

Abstract

The invention provides compositions and methods for the treatment of mild cognitive impairment (MCI), and for inhibiting, reducing, delaying and/or preventing the progression of MCI to Alzheimer's disease. The methods entail administering an effective amount of one or more compounds selected from the group consisting of tropisetron, disulfuram, honokiol and nimetazepam. The methods also are useful for prophylactic and therapeutic treatment of amyloidogenic diseases, including Alzheimer's disease.

First claim

What is claimed is:

1. A method of treating mild cognitive impairment (MCI) associated with amyloid deposits in the brain in a subject, the method comprising:
administering tropisetron or a pharmaceutically acceptable salt thereof, to the subject diagnosed as having MCI, where said tropisetron or pharmaceutically acceptable salt thereof is administered in an amount effective to increase in the cerebral spinal fluid (CSF) levels of one or more components selected from the group consisting of sAPPα, sAPPα/sAPPβ ratio, sAPPα/Aβ40 ratio, and sAPPα/Aβ42 ratio.

2. The method of claim 1 , wherein said tropisetron is provided as a pharmaceutically acceptable HCl salt.

3. The method of claim 1 , wherein the subject is human.

4. The method of claim 1 , wherein administration of said tropisetron prevents the progression of MCI to Alzheimer' s disease.

5. The method of claim 1 , wherein the subject is at risk of developing Alzheimer' s disease.

6. The method of claim 5 , wherein the subject has a familial risk for having Alzheimer's disease.

7. The method of claim 5 , wherein the subject has a familial Alzheimer's disease (FAD) mutation.

8. The method of claim 5 , wherein the subject has the APOE ε4 allele.

9. The method of claim 1 , wherein the subject is free of and does not have genetic risk factors of Parkinson's disease or schizophrenia.

10. The method of claim 1 , wherein the subject is not diagnosed as having or at risk for Parkinson's disease or schizophrenia.

11. The method of claim 1 , wherein the subject does not have a neurological disease or disorder other than Alzheimer' s disease.

12. The method of claim 1 , wherein the subject is not diagnosed as having or at risk for a neurological disease or disorder other than Alzheimer's disease.

13. The method of claim 1 , wherein said method provides one or more of the following:
a reduction of the plaque load in the brain of the subject;
a reduction in the rate of plaque formation in the brain of the subject;
an improvement in the cognitive abilities of the subject;
an improvement in a stabilization of, or a reduction in the rate of decline of the clinical dementia rating (CDR) of the subject; and
where the subject is a human the mitigation comprises a perceived improvement in quality of life by the human.

14. The method of claim 1 , wherein the tropisetron is administered orally.

15. The method of claim 1 , wherein the administering is over a period of at least three weeks.

16. The method of claim 1 , wherein the administering is over a period of at least 6 months.

17. The method of claim 1 , wherein said tropisetron is formulated for administration via a route selected from the group consisting of isophoretic delivery, transdermal delivery, aerosol administration, administration via inhalation, oral administration, intravenous administration, and rectal administration.

18. The method of claim 1 , wherein an acetylcholinesterase inhibitor is not administered in conjunction with said tropisetron.

19. The method of claim 18 , wherein the acetylcholinesterase inhibitor is selected from the group consisting of tacrine, ipidacrine, galantamine, donepezil, icopezil, zanapezil, rivastigmine, huperzine A, phenserine, physostigmine, neostigmine, pyridostigmine, ambenonium, demarcarium, edrophonium, ladostigil and ungeremine.

20. A method of delaying the onset of MCI, or Alzheimer's disease in an asymptomatic subject, the method comprising:
administering to said asymptomatic subject an amount of tropisetron, or its pharmaceutically acceptable salt, effective to increase in the cerebral spinal fluid (CSF) levels of one or more components selected from the group consisting of sAPPα, sAPPα/sAPPβ ratio, sAPPα/Aβ40 ratio, and sAPPα/Aβ42 ratio.

21. The method of claim 20 , wherein the subject is at risk of developing mild cognitive impairment (MCI) associated with amyloid deposits in the brain, or Alzheimer's disease.

22. The method of claim 20 , wherein the subject is a human and progression from an asymptomatic state to a symptomatic state of MCI is delayed.

23. The method of claim 20 , wherein said tropisetron is administered orally.

24. The method of claim 20 , wherein the administering is over a period of at least three weeks.

Assignees

• John Varghese
• Bredesen Dale E
• Buck Inst Res Aging

Inventors

• John Varghese
• Bredesen Dale E

Classifications

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• A61K31/4035 Primary

  Isoindoles, e.g. phthalimide · CPC title

• A61P25/00

  Drugs for disorders of the nervous system · CPC title

• A61K31/145

  having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2) (isothiourea A61K31/155) · CPC title

• A61K31/5513

  1,4-Benzodiazepines, e.g. diazepam {or clozapine} · CPC title